🔴Promising new data:
Red light therapy is showing real results in Parkinson's disease clinical trials —
gait improves, tremors ease, and new brain imaging suggests it may actually protect dopamine neurons.
This isn't fringe science.
It's peer-reviewed.
Here's what the data shows 🧵👇
#Parkinsons #NeurologyResearch
Recent studies have provided clearer answers on what drives elevated blood cholesterol levels. The long-standing warnings about eggs and dietary cholesterol have largely been overstated. Instead, saturated fat is the primary culprit behind rises in artery-clogging LDL cholesterol.
For decades, eggs were viewed as risky due to their cholesterol content. However, rigorous clinical trials now show that dietary cholesterol has minimal impact on blood LDL levels for most people. The liver tightly regulates its own cholesterol production and compensates for intake from food. In contrast, saturated fats, found in red meat, butter, full-fat dairy, and many processed foods, strongly raise LDL cholesterol. Replacing them with soluble fiber (such as oats and beans) and polyunsaturated fats (from nuts, seeds, and fatty fish) helps the liver remove excess LDL more effectively.
A notable 2025 randomized crossover trial demonstrated this clearly: consuming two eggs per day as part of a low-saturated-fat diet actually lowered LDL cholesterol compared to a high-saturated-fat diet with minimal eggs. Across diets, saturated fat intake correlated strongly with higher LDL, while dietary cholesterol did not.
The picture becomes more nuanced with low-carbohydrate diets. While keto-style eating often leads to weight loss, it can paradoxically increase cholesterol levels in some individuals, particularly leaner people. Researchers link this effect to shifts in the gut microbiome, including reduced levels of beneficial Bifidobacteria that help metabolize cholesterol.
These findings highlight the importance of personalized nutrition. Most people can safely enjoy eggs as part of a balanced diet focused on minimizing saturated fat and maximizing fiber and unsaturated fats. Managing cardiovascular health requires looking beyond single nutrients and considering overall dietary patterns.
[Carter, S., et al. (2025). Impact of dietary cholesterol from eggs and saturated fat on LDL cholesterol concentrations. The American Journal of Clinical Nutrition. DOI: 10.1016/j.ajcnut.2025.02.001]
🚨 BREAKING Scientists may have just cracked the code on Alzheimer's and Parkinson's — WITH ONE PILL.
A drug called Buntanetap was just published in a peer-reviewed journal with Phase 3 data.
Phase 3 means that we are on the verge of FDA approval.
It targets the ROOT CAUSE of both diseases simultaneously.
Here's what you need to know 🧵👇
#Alzheimers #Parkinsons
Retatrutide's liver data is unlike anything we've seen from a weight loss drug:
- 86% liver fat reduction at 48 weeks, most of it within the first 24 weeks
- 93% of patients achieved completely normal liver fat levels
For context, tirzepatide reduces liver fat by 45–57%.
One in three adults has fatty liver disease and most don't know it.
The reason for this is retatrutide's glucagon receptor. It tells the liver directly to burn its stored fat, not just reduce calories coming in.
🚨💊HUGE news: @US_FDA has finally granted approval to @ShionogiUS’s Xocova (Ensitrelvir), a 2nd-generation antiviral targeting SARS-CoV-2.
The approval is for the indication of “post-exposure prophylaxis of COVID-19 following contact with an individual who has COVID-19”. However, just like with any drug, it can obviously also be used off-label (e.g. treatment of both acute COVID or Long COVID).
In Japan, Xocova received Emergency Use Authorization for the treatment of acute COVID all the way back in November 2022, received full approval in March 2024, and an expansion to include post-exposure prophylaxis in March 2026.
The post-exposure prophylaxis indications are based on the SCORPIO-PEP trial (https://t.co/Dxv0lhS2CM), where Xocova reduced the incidence of COVID-19 after household exposure by 67%, from 9.0% down to 2.9%.
Mechanically, Xocova is the same class of drug as Paxlovid - a 3C-like protease inhibitor that inhibits viral replication. From our best understanding, Xocova is probably slightly more potent than Paxlovid, but the more definitive advantage is that it comes with less side effects and less drug interactions (which are caused by the Ritonavir component of Paxlovid, added to boost the concentration of the actual antiviral, Nirmatrelvir).
Xocova should be useful for lowering viral load during an acute infection, especially if taken within a couple or days of symptom onset, which may help shorten the duration of acute symptoms. Will it do anything to prevent long-term damage or the development of Long COVID? Almost certainly not, just like Paxlovid, but I’d be more inclined to tell people that it’s worth trying if we’re no longer dealing with the side effect profile of Paxlovid.
Where it makes the most sense to use Xocova, just like with Paxlovid, is as a component of polytherapy for Long COVID driven by viral persistence. The big issue there, however, is that you need a longer course of these antivirals than most physicians are willing to prescribe and/or most insurance companies are willing to cover. And they’re generally not very effective as a monotherapy, you need to pair these oral antivirals with other therapies for better coverage and tissue penetration (eg. monoclonal antibodies and Nuvaxovid, and potentially even a 2nd antiviral like Remdesivir).
All in all, this is a very important and long overdue approval. It’s not a game-changing silver bullet, and notably, nobody should really be expecting to use or rely on Xocova in a way that they wouldn’t be open to using or relying on Paxlovid in the present. But there are plenty of applications for it, and Xocova should absolutely be seen as another Swiss cheese layer / tool in the toolbox for COVID conscious community members and any allied medical providers.
HUS:n sairaalaan ei saa enää tuoda kukkia ilahduttamaan potilaita, koska niissä on infektioriski. Sen sijaan sekä henkilökunta että vierailijat voivat rauhassa tartuttaa aerosoleista tarttuvia infektiotauteja jatkossakin, sillä ffp-maskeja ei sairaalassa tarvitse käyttää.
Kuuntelen tässä hyvinvointialueen johtajan selittelyä Ylen aamussa ja suoraan sanoen vähättelyltä kuulostaa, eikä oikeasti tehdä mitään. Kun kuolevien vanhusten morfiineja jatketaan vedellä, koko homma pitäisi panna kerrasta poikki. #hoiva
BREAKING
Your doctor prescribes a statin to protect your heart.
But the same drug is now linked to BOTH protecting AND damaging the brain.
Here is what 7 million patients, major clinical trials, and the FDA actually found — and why the truth is more nuanced than any headline.
🧵 Thread (1/12)
Perjantainen #tartuntatautikatsaus
-ei #koronafi dataa, määrä nykytasoilla matala viime viikolla
-influ huojuu yksittäisellä alueella kohtalaisen tasolla
-tt-rekistärissä ei yllätyksiä, uutena lisätty puumala kun hantavirukset välillä keskusteluttaa
Scientists from DRC and Uganda have released the first complete genomes of #Bundibugyo#Ebola virus from the May 2026 outbreak, indicating a possible new #spillover event from wild animals as case numbers continue to rise.
The genomes, posted on virological website on 17 May 2026, display a distinct genetic lineage that does NOT match any previously sequenced Bundibugyo strains, suggesting a recent introduction from an animal reservoir into humans rather than sustained human‑to‑human transmission. Phylogenetic analysis shows that the new sequences form a separate cluster, supporting the inference of a fresh zoonotic spillover.
The most plausible source of this spillover is wildlife inhabiting the Ituri forest, particularly fruit bats or other mammals known to harbor filoviruses, which could have been implicated in earlier outbreaks through hunting or contact with infected animal tissues. Ongoing ecological surveillance in the region will be essential to identify the exact reservoir and to mitigate the risk of future spillover events.
More genetic details on https://t.co/srNXd70GTj
#DRC #Uganda #outbreak #PHEIC
The clinical trial results were published in the New England Journal of Medicine.
15 patients.
All had cholesterol disorders that DIDN'T respond to standard drugs.
After ONE infusion:
📉 LDL cholesterol: DOWN 49% (max -87%)
📉 Triglycerides: DOWN 55% (max -84%)
📉 ANGPTL3 protein: DOWN 73% (max -89%)
Effects kicked in within 2 WEEKS.
Still holding at 60 days follow-up.
Chewing gum restores dad’s taste and smell years after Covid.
A 12-week study found using super-strength flavoured chewing gums helps rebuild brain connections linked to taste and smell. In the trial, 67% of participants reported improved smell and 83% saw improvements in taste.
#tartuntatautikatsaus poikkeyksellisesti vasta näin maanantaina
-kesä alkaa näkyä joka puolella
-#koronafi ei ole aikoihin ollut näin alhaalla, toivottavasti pysyy
-influ laskenut
-liki kaikki muutkin laskusuunnassa